Boone Capital Management Buys Stake in ClearPoint Neuro

The investment firm added over 283,000 shares of the medical technology company to its portfolio.

Mar. 15, 2026 at 8:58am

Got story updates? Submit your updates here. ›

Boone Capital Management LLC, an institutional investor, purchased a new stake of 283,912 shares in ClearPoint Neuro, Inc. (NASDAQ:CLPT) during the third quarter. The shares were valued at approximately $6.19 million, making ClearPoint Neuro the 15th largest holding in Boone Capital's investment portfolio, representing around 2% of the firm's total holdings.

Why it matters

This investment by Boone Capital Management, a respected institutional investor, signals confidence in ClearPoint Neuro's potential as a medical technology company focused on MRI-guided neurosurgical procedures. The stake represents a significant position that could influence the company's future direction and performance.

The details

According to a 13F filing with the SEC, Boone Capital Management purchased 283,912 shares of ClearPoint Neuro during the third quarter. This gives the firm a 1% ownership stake in the company. ClearPoint Neuro develops and commercializes an MRI-guided therapy platform for minimally invasive neurosurgical procedures, including deep brain stimulation, laser ablation, and brain tumor treatments.

  • Boone Capital Management purchased the ClearPoint Neuro shares during the third quarter of the year.

The players

Boone Capital Management LLC

An institutional investment firm that manages a diversified portfolio of public and private investments.

ClearPoint Neuro, Inc.

A medical technology company that specializes in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures.

Got photos? Submit your photos here. ›

The takeaway

Boone Capital Management's investment in ClearPoint Neuro reflects the firm's belief in the company's potential as a leader in the growing field of MRI-guided neurosurgical technologies. This sizable stake could signal increased institutional interest and support for ClearPoint Neuro as it continues to develop and commercialize its innovative medical solutions.